**RESPONSE TO BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH FAILURE TO CONVENTIONAL SYNTHETIC DMARD AND/OR BIOLOGICAL DMARD: DATA FROM A LOCAL REGISTRY**

Jose Rosas1, José Miguel Senabre-Gallego1, Gregorio Santos Soler1, José Antonio Bernal-Vidal1, Esteban Salas-Heredia1, Ana Pons1, Catalina Cano1, Estibaliz Ivars1, José Alberto García-Gómez2, Xavier Barber2, AIRE-MB, Hospital Marina Baixa, Rheumatology, Villajoyosa, Spain; Hospital General Universitario, Infectious Diseases, Elche, Spain; Miguel Hernández University, Statistics, Elche, Spain

**Objectives:** To know the characteristics of patients with rheumatoid arthritis (RA), in treatment with baricitinib (BARI), who have failed to conventional synthetic DMARD (DMARDcs) and/or biological DMARDs (DMARD).

**Methods:** Prospective observational study, in real life, of patients with RA and treatment were collected (time of evolution, duration (p = 0.017), young onset of RA (p <0.001), presence of joint deformities (p = 0.034), presence of osteoporosis (p = 0.029), presence of digestive intolerance to methotrexate leading to a serious neurological complication. Although digestive intolerance to methotrexate is considered benign, it can be daunting. Knowledge of complications and close monitoring of patients must be imperative. Gayet Wernicke encephalopathy is a rare and serious pathology. We should keep it in mind and prevent it in risky situations.

**REFERENCES**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.7281

---

**GAYET WERNICKE’S ENCEPHALOPATHY SECONDARY TO METHOTREXATE INTOLERANCE: A SERIOUS COMPLICATION OF CHRONIC VOMITING**

Houda Sahraoui, Imane El Bouchi, Mohamed VI University Hospital Center, Marrakech, Morocco, rheumatology, Marrakech, Morocco

**Background:** Gayet-Wernicke’s encephalopathy is a serious complication of thiamine deficiency. Chronic alcoholism is recognized as the most common cause of Gayet-Wernicke’s encephalopathy, but other causes including malnutrition, chronic vomiting, prolonged fasting, and exclusive artificial feeding have been documented.

**Objectives:** We report a case of Gayet-Wernicke’s encephalopathy complicating uncontrollable vomiting secondary to severe Methotrexate intolerance.

**Methods:** Case report

**Results:** A 47-year-old women with rheumatoid arthritis. She was put under methotrexate at the dose of 15 mg/week, 1 month prior to admission into our department for the management of an acute febrile polyarthritis associated to severe and uncontrollable gastrointestinal intolerance to Methotrexate. There was no abdominal pain or transit problem. One month later, she experienced tempo-spatial disorientation, somnolence, horizontal nystagmus, and vertigo attacks with visual hallucinations and memory problems. The muscular forces at the four limbs were decreased to 3/5 with abolished osteotendinous reflexes at the two lower limbs. MRI showed hyperintense signals on T2 and FLAIR image in thalamus, periaqueductal area and mamillary bodies. Electroneuromyography (ENMG) showed axonal motor neuropathy in all 4 limbs. The hemogram showed normochromic normocytic anemia. Laboratory testing for Vitamin B12, vitamin D, folate and minerals showed multiple deficiencies. A multivitamin supplementation was introduced with good evolution.

**Conclusion:** This is the first case of severe digestive intolerance to methotrexate leading to a serious neurological complication. Although digestive intolerance to methotrexate is considered benign, it can be daunting. Knowledge of complications and close monitoring of patients must be imperative. Gayet Wernicke encephalopathy is a rare and serious pathology. We should keep it in mind and prevent it in risky situations.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.7756

---

**RISK FACTORS OF JOINT SURGERY IN RHEUMATOID ARTHRITIS TUNISIAN PATIENTS**

Olf Safdane1, Leila Gatsi2, Rim Barhourmi1, Aicha Ben Tekaya1, Rawda Tekaya1, Ines Mahmoud1, Leila Abdelmoula1, Charles Nicole Hospital, Rheumatology Department, Tunis, Tunisia; Polyvalent El Omrane, Rheumatology Department, Tunis, Tunisia

**Background:** Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by poyarticular synovial inflammation and progressive joint destruction. Orthopedic surgery is an integral part of the treatment of RA and it is mainly reserved for severe and advanced forms where there is a failure of medical treatment.

**Objectives:** To assess the rate of joint surgery in rheumatoid arthritis (RA) Tunisian patients and to determine the risk factors of surgical treatment.

**Methods:** A retrospective cross sectional study over a period of 15 years including 500 Tunisian patients with RA conducted. The prevalence of joint surgery indication has been evaluated. Clinical, paraclinical and therapeutic characteristics of RA were compared according to the need of surgical treatment.

**Results:** Mean age was 53.4 years. Female to male ratio was 5. The indication of joint surgery was noted in 59 patients (12%). Factors associated with joint surgery were delayed diagnosis (p = 0.037), long RA duration (p = 0.017), young onset of RA (p <0.001), presence of joint deformities (p = 0.034), presence of osteoporosis (p = 0.029), presence
remarkable outcomes in patients with RA

real-life use of baricitinib in rheumatoid arthritis: a multicenter observational study of 150 patients

remarkable outcomes in patients with RA

real-life use of baricitinib in rheumatoid arthritis: a multicenter observational study of 150 patients

References


Disclosure of Interests: None declared


remarkable outcomes in patients with RA

real-life use of baricitinib in rheumatoid arthritis: a multicenter observational study of 150 patients

References


Disclosure of Interests: None declared


AB0045

REMARKABLE OUTCOMES IN PATIENTS WITH RA USING CONVENTIONAL DMARDS UNDER A T2T STRATEGY AND A DISEASE MANAGEMENT MODEL – RESULTS FROM A FIVE YEAR REAL-WORLD REGISTRY

Pedro Santos-Moreno1, Michael Cabrera2, Diana Buitrago-Garcia2, Eva Cardozo3, Ivana Ramirez4, Danny Gomez4, Edwin Castillo5, Sandra Farietta1,2.

Background: Rheumatoid arthritis (RA) is a common chronic inflammatory disease. Treat-to-target (T2T) is a management strategy for R that proposes as the therapeutic target a state of remission or low disease activity, additionally a multidisciplinary management of patients with RA has demonstrated to be an additional aid to achieve remission or low disease activity. Real-world evidence (RWE) refers to information coming from electronic health records, billing data, registries among others. RWE shows results that are difficult for clinical trials to demonstrate due to ideal conditions (1, 2).

Objectives: The aim of this study was to describe global change in Disease Activity Score 28 (DAS28) using T2T strategy during 5 years in a cohort of patients receiving conventional DMARDs that attend to a specialized RA center.

Methods: A descriptive cohort study was conducted. Medical records of patients from specialized in RA center were reviewed during 2015-2017; those patients were followed-up under T2T standards and a multidisciplinary approach. Clinical follow-up was designed by the authors according to DAS28 as follows: every 3-5 weeks (DAS28 > 5.1), every 7-9 weeks (DAS28 > 3.1), and every 11-13 weeks (DAS28 < 3.1). Tender joint count (TJC), swollen joint count (SJC) and DAS28 were measured on each visit. Therapy had to be adjusted with DAS28 > 3.2 unless patient’s conditions don’t permit it; we considered this follow-up strategy as type of implementation of a T2T strategy in patients with RA. Patients entered into a multidisciplinary program of care with periodic consultations not only to rheumatologist but with a physiatrist, psychologist, physiotherapist, occupational therapy nutrition, and, a patient focused program. With a multidisciplinary model of care the patient is seen as a whole, and the expertation is to achieve the best results in the management of RA. We divided patients in four groups: remission (REM), low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA). Patients and the aim of the study was to look at what percentage of patients who were in moderate or severe disease activity reached a low disease activity or remission. Descriptive epidemiology was done, we calculated means, and standard deviations for continuous variables and categorical variables were presented as rates. We compared disease activity at baseline and at end of follow-up.

Results: During 5 years we included 2,128 patients. 83% were female and 17% were male, mean age was 57 years ±14. At baseline median DAS28 4.34 RIQ (3.76-5.06) and at 5 years 2.02 RIQ (1.46-2.38). At the end of our follow-up 81% were remission and 7% in LDA. See table 1.

I our study DAS28 was not normally distributed, thus we performed a Wilcoxon test in order to compare the mean DAS28 at baseline/5-year showing statistical significance (P=0.05).

ACTIVITY LEVEL

<table>
<thead>
<tr>
<th></th>
<th>BASELINE</th>
<th>3 YEARS FOLLOW-UP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>REM</td>
<td>1,728</td>
<td>81</td>
</tr>
<tr>
<td>LDA</td>
<td>5</td>
<td>0.24</td>
</tr>
<tr>
<td>MDA</td>
<td>1,628</td>
<td>76.37</td>
</tr>
<tr>
<td>HDA</td>
<td>495</td>
<td>23.39</td>
</tr>
</tbody>
</table>

Conclusion: In our patients T2T improves associated with a disease management model, improves disease activity in patients with RA. This evidence from a real-life setting that shows the advantages of treating RA patients with a multidisciplinary team under a T2T model with a low-cost treatment. It is important to explore other predictors that can improve disease activity.

Disclosure of Interests: Pedro Santos-Moreno Grant/research support from: Dr Santos has received research grants from University of Milan, Abbvie and UCB, Speakers bureau: Dr Santos has received speaker fees from Sanofi, Lilly, Bristol, Pfizer, Abbvie, Janssen and UCB, Michael Cabrera: None declared, Diana Buitrago-Garcia: None declared, Eva Cardozo: None declared, Ivana Ramirez: None declared, Danny Gomez: None declared, Edwin Castillo: None declared, Sandra Farietta: None declared


AB0446

REAL-LIFE USE OF BARICITINIB IN RHEUMATOID ARTHRITIS: A MULTICENTER OBSERVATIONAL STUDY OF 150 PATIENTS

Gaetano Mario Guidelli1, Elena Generali1, Chiara Bazzani2, Roberto Goris3, Garifalla Sakellarious4, Massimiliano Limonta5, Maria Sole Chimenti2, Roberto Perricone6, Edoardo Conticini6, Bruno Frediani7, Nicola Boffini8, Lorenzo Dagna8, Marta Riva8, Maria Rosa Pozzi8, Rossana Daniela Grembiale3, Teodora Serban3, Gerolamo Bianchi9, Carlo Selmi1,10,16

1Humanitas Clinical and Research Center, Rheumatology and Clinical Immunology Unit, Rozzano (MI), Italy; 2Spedali Civili, Rheumatology Unit, Brescia, Italy; 3ASST Papa Giovanni XXIII, Rheumatology Unit, Bergamo, Italy; 4Policoni Tor Vergata, Rheumatology Unit, Rome, Italy; 5Policoni Le Scotte, Rheumatology Unit, Siena, Italy; 6IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milan, Italy; 7San Gerardo Hospital, Rheumatology Unit, Monza, Italy; 8University “Magna Graecia”, Health Science, Catanzaro, Italy; 9ASL3 Genovese, Division of Rheumatology, Genova, Italy; 10University of Milan, BIOMETRA Department, Milan, Italy

Background: Baricitinib is an oral selective JAK1/2 inhibitor recently approved in the EU for the treatment of rheumatoid arthritis (RA). No real-life data are available about its efficacy and safety.

Objectives: To investigate the efficacy and safety profiles of baricitinib in real-life setting.

Methods: We performed a multicenter prospective observational study on adult RA patients starting JAK inhibitors between 12/2017 and 12/2018. Demographic and clinical data as well as laboratory values and adverse events were collected at baseline and after 12 and 24 weeks. Disease activity was measured by DAS28-CRP at baseline, after 12 and 24 weeks.

Results: We obtained data from 150 patients with RA (women 116 – 77.3%; median age 60 years, inter-quartile range IQR 54-68; median disease duration 10 years, IQR 4-18) treated with baricitinib 2 or 4 mg QD, however only 2/150 (1.3%) at the reduced dosage. At the time of database lock 95/150 (63%) patients have completed the 12 weeks follow-up, 38/150 (25%) patients have completed the 24 weeks follow-up. Baricitinib was started after at least one conventional synthetic DMARD in all 148/150 cases (99%), being in all of cases methotrexate, while was started prior to a biologic DMARD in 57 (38%) patients. It was prescribed as a second line in 17/93 (18%) patients, third in 27 (29%), fourth or higher in 49 (53%). Baricitinib was prescribed as monotherapy in 57/150 (38%) patients, while combined with methotrexate in 65/150 (43%), at a median dosage of 15 mg/week. Oral corticosteroids were used by 105/150 (70%) patients, at a median dosage of 5 mg/day. Mean DAS28-CRP at baseline was 4.92 (standard deviation 1.22), with 65 (43.3%) patients having a DAS28-CRP>5.1. At both 12 and 24 weeks, a significant reduction of disease activity scores was observed (DAS28-CRP mean 3.07, SD 1.36, and 2.85, SD 1.35, respectively; p-values<0.001). Eleven (16%) (n=16) patients discontinued the treatment, with 8 (50%) due to primary inefficacy, mainly in the first 3 months of therapy (5/8– 63%). Adverse events were observed in 19/150 (13%) patients, 7 being non-serious infections (4...